The tumor suppressive function of the chromatin modifier SETD2, at least in the context of KRAS-driven lung adenocarcinoma, is therefore to limit pro-proliferative metabolic pathways by restricting oxidative metabolism and protein synthesis. Here, KRAS is linked to neoplasm.